Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives

<table>Schematic representation of the putative mechanisms mediating rituximab’s anticancer activity in NHL cells. The anti-CD20 monoclonal antibody rituximab has several mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC), which involves recruitment of effector cells, mediated by Fc<i>γ</i> receptors; complement-dependent cytotoxicity (CDC); apoptosis induction.</table>

Journal of Immunology Research

fig1

Figure 1

Figure 1: Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives 